Accelerating the Development and Delivery of

Effective Oncology Treatments

to Patients

Cancer Drug Development Forum (CDDF) is a neutral, non–competitive platform

for multi-stakeholder discussions and collaboration in the development of cancer drugs.

About CDDF

Learn about CDDF

Unique Multi-Stakeholder Platform

Patients

Patients are the cornerstone of CDDF’s mission and central to our multi-stakeholder discussions. Patients and advocacy groups are invited to join the CDDF multi-stakeholder community and make their voices heard. Check out collaborative opportunities and grants available to patients.

Industry

The CDDF provides the healthcare industry with unique opportunities to collaborate with diverse stakeholders and take part in open dialogue to accelerate oncology drug development. Discover the CDDF Industry Membership Program and engage with key experts in oncology.

Academia

The CDDF fosters advancement and innovation in cancer research by creating a collaborative platform for academics to share knowledge and expertise with a multi-stakeholder audience. Join CDDF’s discussions on the latest developments and explore opportunities to contribute.

Regulators & HTAs

The CDDF convenes discussions on key topics in oncology, fostering a balanced exchange of perspectives. Regulators and HTA agencies can gain valuable insights and stay informed on emerging trends through our productive dialogue. Explore collaboration opportunities and join our community.

CANCER DRUG DEVELOPMENT FORUM

The leading non-competitive drug development platform working to stimulate the advancement and accessibility of cancer treatment.



Discover more about the CDDF



Explore our upcoming programmes



Join the CDDF community

REGISTER

[MESSAGE FROM ACT EU – Request for stakeholders’ input on the guideline to simplify the clinical trials application package for use during Public Health Emergencies (PHEs).]

by Hyunmin Park | 2nd June 2026 | ACT-EU News, CDDF News | 0 Comments

ACT EU has developed the guideline to simplify the clinical trials application package for use during PHEs. The package consists of: 1️⃣ A guidance document on the simplified application package for clinical trials targeting a PHE 2️⃣ Annex I: Part I language...

CDDF’s New Board Announcement: Welcoming Dr. Agnes Saint-Raymond and Ms. Jana Pelouchova

by Hyunmin Park | 27th May 2026 | CDDF News | 0 Comments

🔔📢 CDDF’s New Board Announcement: Welcoming Dr. Agnes Saint-Raymond and Ms. Jana Pelouchova The Cancer Drug Development Forum (CDDF) is pleased to announce the appointment of Dr. Agnes Saint-Raymond and Ms. Jana Pelouchova to its Board of Directors. We look forward to...

Key Takeaways from CDDF Live Webinar Series – “AI and Big Data AI in Drug Development: Use of AI in Clinical Trials” (12 May 2026)

by Hyunmin Park | 15th May 2026 | CDDF News | 0 Comments

The CDDF is pleased to share the key takeaways from our live webinar series – “AI and Big Data AI in Drug Development: Use of AI in clinical trials” held on 12 May 2026. This webinar included a lecture by Dr. James Gulley (NIH) followed by a 30-minute Q&A...

[ACT EU Workplan for 2026-2027 – Version 4, May 2026]

by Hyunmin Park | 13th May 2026 | ACT-EU News, Oncology News | 0 Comments

The ACT EU workplan for 2026 – 2027 has been adopted by the ACT EU Steering Group and is now published. The workplan reflects the revised ACT EU objectives and takes into account recent legislative and policy developments including the proposed Biotech Act, the...

Executive Summary: CDDF & AAADV Workshop – Challenges in the Landscape of a Global Development Strategy Including Patient Access (30-31 March 2026, BE)

by Hyunmin Park | 8th April 2026 | CDDF News | 0 Comments

The Cancer Drug Development Forum (CDDF) is delighted to announce that the executive summary of the CDDF & AAADV joint workshop on “Challenges in the Landscape of a Global Development Strategy Including Patient Access” has been published today. This...

[News from ACT EU] – Clinical Trials Information System (CTIS): training and support

by Hyunmin Park | 7th April 2026 | ACT-EU News, Oncology News | 0 Comments

Check out the publication of a new EMA document of frequently asked questions (FAQ) for sponsors on the Clinical Trials Information System (CTIS):...

Interim Report: ACT EU pilots on consolidated scientific and regulatory advice

by Hyunmin Park | 17th March 2026 | ACT-EU News, CDDF News | 0 Comments

The interim results from the ACT EU pilots on consolidated scientific and regulatory advice have been published and available to stakeholders. These pilots were launched to offer harmonised advice on how to improve the quality of applications for clinical trials and...

[CDDF NEW WHITE PAPER: Challenges and Potential Solutions to Advance Global Cancer Drug Development]

by Hyunmin Park | 11th March 2026 | CDDF News | 0 Comments

We are delighted to announce that CDDF’s new white paper, Challenges and Potential Solutions to Advance Global Cancer Drug Development, has been published in the journal Therapeutic Innovation & Regulatory Science. This paper reflects on multi-stakeholder...

CDDF Diversity Initiative: In-Person Meeting in Brussels Today

by Hyunmin Park | 5th March 2026 | CDDF Diversity Initiative, CDDF News | 0 Comments

Following several work package meetings over the past 10 months, the final project meeting for the Diversity Initiative is in full swing in Brussels. Our multi-stakeholder working group members and experts have gathered to advance their work on developing and...

[EMA News] Public Consultation: Concept Paper on Guideline Revision on Good Pharmacogenomic Practice

by Hyunmin Park | 4th March 2026 | Oncology News | 0 Comments

🔔📢The European Medicines Agency has published for public consultation: a Concept paper on the guideline revision on good pharmacogenomic practice. Since its initial publication in 2018, the guideline on good pharmacogenomic practice has played a crucial role in...

I

The Cancer Drug Development Forum – CDDF is the platform for all stakeholders involved in the development of cancer drugs.

Accelerating the Development and Delivery of

Effective Oncology Treatments

to Patients

Learn about CDDF

Unique Multi-Stakeholder Platform

Patients

Industry

Academia

Regulators & HTAs

CANCER DRUG DEVELOPMENT FORUM

The leading non-competitive drug development platform working to stimulate the advancement and accessibility of cancer treatment.

Discover more about the CDDF

Explore our upcoming programmes

Join the CDDF community

[MESSAGE FROM ACT EU – Request for stakeholders’ input on the guideline to simplify the clinical trials application package for use during Public Health Emergencies (PHEs).]

CDDF’s New Board Announcement: Welcoming Dr. Agnes Saint-Raymond and Ms. Jana Pelouchova

Key Takeaways from CDDF Live Webinar Series – “AI and Big Data AI in Drug Development: Use of AI in Clinical Trials” (12 May 2026)

[ACT EU Workplan for 2026-2027 – Version 4, May 2026]

Executive Summary: CDDF & AAADV Workshop – Challenges in the Landscape of a Global Development Strategy Including Patient Access (30-31 March 2026, BE)

[News from ACT EU] – Clinical Trials Information System (CTIS): training and support

Interim Report: ACT EU pilots on consolidated scientific and regulatory advice

[CDDF NEW WHITE PAPER: Challenges and Potential Solutions to Advance Global Cancer Drug Development]

CDDF Diversity Initiative: In-Person Meeting in Brussels Today

[EMA News] Public Consultation: Concept Paper on Guideline Revision on Good Pharmacogenomic Practice

CDDF Webinar: Use of AI in Clinical Trials (May 2026)

CDDF & Oncology News

CDDF Brochure

Join the CDDF community to find ways to accelerate oncology drug development and deliver optimal treatment to cancer patients

Subscribe to our mailing list

This form is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Subscribe to our mailing list

COLLABORATION IS THE KEY

TO IMPROVING OUTCOMES

FOR CANCER PATIENTS